Back to top
more

Hologic (HOLX)

(Delayed Data from NSDQ)

$68.98 USD

68.98
1,747,081

+1.03 (1.52%)

Updated Aug 13, 2025 04:00 PM ET

After-Market: $69.00 +0.02 (0.03%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy23.75%
2Buy17.82%
3Hold9.58%
4Sell5.28%
5Strong Sell2.61%
S&P50011.30%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

  • Value Score A
  • Growth Score A
  • Momentum Score A
  • VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

B Value C Growth B Momentum B VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Bottom 38% (153 out of 245)

Industry: Medical - Instruments

Zacks News

Zacks Equity Research

Here's Why You Should Retain Insulet (PODD) Stock for Now

Investors continue to be optimistic about Insulet (PODD) on the robust performance of Omnipod 5.

Zacks Equity Research

3 Reasons to Hold Inspire Medical (INSP) Stock in Your Portfolio

Investors continue to be optimistic about Inspire Medical (INSP) on the back of its product innovations.

Zacks Equity Research

BD's (BDX) Latest Product Launch to Boost Research Outcome

BD's (BDX) latest cell sorting technology is expected to speed up the process of cell sorting and allow researchers to answer complex biological questions.

Zacks Equity Research

Hologic (HOLX) Gets FDA Nod for Multiplexed Respiratory Test

Hologic's (HOLX) Panther Fusion SARS-CoV-2/Flu A/B/RSV assay is done using the fully-automated, high-throughput Panther Fusion system.

Zacks Equity Research

What's in the Cards for Medtronic (MDT) in Q4 Earnings?

Medtronic (MDT) is likely to have prioritized its R&D investments, which might get reflected in the fiscal Q4 results.

Zacks Equity Research

Veeva Systems' (VEEV) New Launch to Improve Patient Outcomes

Veeva Systems' (VEEV) new offering is expected to facilitate effective engagement with customers and KOLs for improved patient journeys.

Zacks Equity Research

Here's Why You Should Retain QIAGEN (QGEN) Stock for Now

QIAGEN (QGEN) is likely to benefit from high organic growth across its non-COVID-19 product group and portfolio advancements, reflecting a positive share price movement.

Zacks Equity Research

BD's (BDX) New FDA Approval to Improve MRSA Diagnostics

BD's (BDX) receipt of the latest FDA approval is likely to improve laboratory workflow.

Zacks Equity Research

Here's Why You Should Retain Myriad Genetics (MYGN) Stock Now

Myriad Genetics (MYGN) is likely to benefit from testing volumes across product segments and the latest partnerships, reflecting a positive share price movement.

Zacks Equity Research

NextGen (NXGN) Q4 Earnings Top Estimates, Revenues Surge Y/Y

NextGen's (NXGN) fourth-quarter fiscal 2023 results reflect strength in both its revenue sources.

Zacks Equity Research

3 Reasons to Retain Masimo (MASI) Stock in Your Portfolio

Investors continue to be optimistic about Masimo (MASI) due to its focus on patient monitoring.

Zacks Equity Research

Hologic (HOLX) Announces Collaboration With NFL CB Kelee Ringo

Hologic (HOLX) and Eagles' CB, Kelee Ringo, come together to highlight the importance of annual mammograms and other routine health screenings.

Zacks Equity Research

Here's Why You Should Retain Charles River (CRL) Stock Now

Charles River's (CRL) share price is likely to grow, backed by strategic acquisitions and the DSA segment's strength.

Zacks Equity Research

LabCorp (LH) Base Business Growth Strong, Margin Pressure Stays

LabCorp (LH) is progressing well with its planned spin-off of the Clinical Development business, which is expected to be completed in mid-2023.

Zacks Equity Research

Here's Why Investors Should Retain Henry Schein (HSIC) for Now

Henry Schein (HSIC) is expected to witness a favorable share price movement, led by optimism surrounding the performance of the dental business and strategic buyouts.

Zacks Equity Research

Hologic, Inc. (HOLX) Is a Trending Stock: Facts to Know Before Betting on It

Zacks.com users have recently been watching Hologic (HOLX) quite a bit. Thus, it is worth knowing the facts that could determine the stock's prospects.

Zacks Equity Research

Abbott (ABT) EPD Business Grows Strong, Macro Issues Stay

Abbott (ABT) continues to make good progress, increasing manufacturing production and recovering market share in the Nutrition business.

Zacks Equity Research

Here's Why Investors Should Retain Syneos Health (SYNH) for Now

Syneos Health's (SYNH) share price movement is expected to be favorable due to the strength of the company's Syneos One portfolio and several value-added partnership deals.

Zacks Equity Research

Hologic, Inc. (HOLX) is Attracting Investor Attention: Here is What You Should Know

Hologic (HOLX) has been one of the stocks most watched by Zacks.com users lately. So, it is worth exploring what lies ahead for the stock.

Zacks Equity Research

Cardinal Health (CAH) Beats on Q3 Earnings, Ups '23 EPS View

Cardinal Health's (CAH) fiscal third-quarter results benefit from the Pharmaceutical segment's solid performance.

Zacks Equity Research

Is Arbutus Biopharma (ABUS) Outperforming Other Medical Stocks This Year?

Here is how Arbutus Biopharma (ABUS) and Hologic (HOLX) have performed compared to their sector so far this year.

Zacks Equity Research

Inari Medical (NARI) Q1 Earnings Top, Revenues Rise Y/Y

Inari Medical's (NARI) first-quarter results benefit from significant progress made across all its growth drivers.

Zacks Equity Research

Glaukos' (GKOS) Q1 Earnings Beat Estimates, Sales Rise Y/Y

Glaukos' (GKOS) Q1 revenues beat estimates but fall year over year. Sales and gross margin improve, while higher operating expenses lead to wider operating loss.

Zacks Equity Research

Here's Why You Should Retain Exact Sciences (EXAS) Stock Now

Investors are optimistic about Exact Sciences (EXAS) on continued strength across the Screening and Precision Oncology businesses.

Zacks Equity Research

HOLX vs. SONVY: Which Stock Is the Better Value Option?

HOLX vs. SONVY: Which Stock Is the Better Value Option?